ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
SAN DIEGO, May 03, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its first quarter financial and operating results after the close of U.S. financial markets on Wednesday, May 10, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | ||
| Date: | May 10, 2017 | |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) | |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) | |
| Passcode: | 15138572 | |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section | |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
